Dr Richard Alan Lundy MacDonell

Published as: Richard Macdonell

VIC, Australia · Non-RMSANZ · FAFRM

Institution(s): AU,ES

MM 1 - Metropolitan(Postcode: 3010)

NeurorehabilitationGenetics and molecular biologyEpidemiology and public healthPharmacology and drug therapyMental health and psychiatry

H-index

256

Publications

9,968

Citations

5.59

FWCI

289

Funding Awards

Clinical Trials

Publication Timeline

Click a bar to filter publications by year

Co-Author Network

1 collaborators · Node size = shared publications

Collaborator	Shared Pubs	Profile
Dr Helen Margaret Dewey	4	View

Clinical Trials (1)

A Phase II study: Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis .

ACTRN12616000151437Recruiting

Conditions: Relapsing Remitting Multiple Sclerosis

Sponsor: Austin Health

Funded by: Austin Health

Funding Awards (289)

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Multiple Sclerosis Australia · 2025(22-2-103)

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

National Health and Medical Research Council · 2025(1129189)

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Multiple Sclerosis Australia · 2025(19-800)

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Universität Basel · 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Postgraduate Institute of Medical Education and Research, Chandigarh · 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

University of Western Australia · 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Isfahan University of Medical Sciences · 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Razi University · 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Sultan Qaboos University · 2025

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Università di Catania · 2025

Identifiers & Metadata

Profile ID:A5003409542

ORCID:0000-0001-6604-3968✓ Verified

Alt. IDs:

A5012929413 A5056442650

Confidence:HIGH

Collaborators:1

Verification:Round 2 CONFIRMED: Profile A5003409542 matches member name 'Dr Richard Alan Lundy MacDonell' (display name 'Richard Macdonell', full name 'Richard A L Macdonell'). database shows multiple AU affiliations (e.g., Univ

Publications (196 shown of 256 total)

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

JAMA Neurology · 2025 · 32 citations

Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis

Neurology Neuroimmunology & Neuroinflammation · 2025 · 12 citations● Rehab-relevant

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2

The Medical Journal of Australia · 2025 · 8 citations

Menopause Impact on Multiple Sclerosis Disability Progression

JAMA Neurology · 2025 · 6 citations● Rehab-relevant

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Neurotherapeutics · 2025 · 6 citations

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1

The Medical Journal of Australia · 2025 · 6 citations

Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis

Neurology Neuroimmunology & Neuroinflammation · 2025 · 5 citations● Rehab-relevant

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Brain · 2025 · 4 citations

Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study

Journal of Neurology · 2025 · 2 citations● Rehab-relevant

Persistent progression independent of relapse activity in multiple sclerosis

Brain Communications · 2025 · 2 citations